Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1

Benzinga Newsdesk www.benzinga.com Positive 90.7%

Neg 0% Neu 0% Pos 90.7%

Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform to Outperform and maintains the price target from $1 to $1.